Jean-Pierre Sommadossi, Atea CEO
Covid-19 roundup: Atea Pharmaceuticals launches antiviral into PhIII trial; Celltrion's antibody shows promise against variant
About a year after jumping into the Covid-19 fight with its lead antiviral, Atea Pharmaceuticals has launched a Phase III trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.